AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Neurocrine’s Crenessity is an oral corticotropin-releasing factor type 1 receptor antagonist. Credit: Piotr Swat/Shutterstock. Neurocrine Biosciences has presented new one-year data from its Phase III ...